HUMANIS
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

HUMANIS Trademark

Serial Number: 97929646

HUMANIS is a trademark filed by HUMANIS SAGLIK ANONIM SIRKETI on May 10, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

HUMANIS SAGLIK ANONIM SIRKETI

Mahmutbey, Balance Günesli,
Istanbul 34100 , TR

Entity Type: 99

Trademark Details

Filing Date

May 10, 2023

Registration Date

Not Registered

Goods & Services

Systemic anti-infectives, namely, antiparasitic, antibacterial and antifungal pharmaceuticals; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, and calcium antagonists being calcium channel blockers; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, pharmaceuticals in the nature of analgesics, psychoanaleptics, and psycoleptics for the treatment of psychosis, anti-epileptics for the treatment of epilepsy, central nervous system drugs being drugs for the treatment of central nervous system disorders, anaesthetics, antiparkinson preparations for the treatment of parkinson's disease, namely, antiparkinson pharmaceuticals; Pharmaceuticals for the treatment of respiratory diseases and asthma; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; insulins; Pharmaceuticals for the treatment of Alimentary Tract and Metabolism; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of blood and blood forming organs; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents, namely, pharmaceuticals for the treatment of cancer; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of sensory organs; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use

Filing History

ABANDONMENT NOTICE E-MAILED - INCOMPLETE RESPONSE
Oct 4, 2024 MAB0
ABANDONMENT - INCOMPLETE RESPONSE
Sep 9, 2024 ABN0
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 29, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 29, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 7, 2024 GNFN
FINAL REFUSAL E-MAILED
Jun 7, 2024 GNFR
FINAL REFUSAL WRITTEN
Jun 7, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 9, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 9, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 9, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 5, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 8, 2023 NWOS
NEW APPLICATION ENTERED
May 13, 2023 NWAP